Abstracts tagged "Disease Activity"

Abstract Number: 1050 • 2016 ACR/ARHP Annual Meeting
Defining Low Disease Activity in Systemic Lupus Erythematosus
Ari Polachek¹, Dafna D Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada
Background/Purpose: Remission is a desirable but not a common enough outcome in systemic lupus erythematosus (SLE) and therefore additional measures are needed to evaluate new…
Abstract Number: 1416 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic
Melissa Wells¹, Rebecca Sadun², Malithi Jayasundara¹, Nicholas Holdgate¹, Samya Mohammad¹, Jason Weiner¹, Tayseer Haroun¹, Stephen Balevic², Lisa Criscione-Schrieber¹ and Mala Kaul¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Measurement of disease activity is considered a quality measure for management of rheumatoid arthritis (RA) patients. One validated measure of RA disease activity is…
Abstract Number: 1696 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Frank Behrens¹, Michaela Koehm², Eva Christina Schwaneck³, Marc Schmalzing⁴, Holger Gnann⁵, Gerd Greger⁶, Hans-Peter Tony⁷ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ⁴Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁵Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁶AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁷Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…
Abstract Number: 2004 • 2016 ACR/ARHP Annual Meeting
Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Miranda van Lunteren¹, Pauline Bakker¹, Zineb Ez-Zaitouni¹, Camilla Fongen², Robert Landewé³, Maikel van Oosterhout⁴, Roberta Ramonda⁵, Floris van Gaalen¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: Disease activity has an important impact on work productivity in patients with Ankylosing Spondylitis (AS). However, if and to what extent this is the…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 2991 • 2016 ACR/ARHP Annual Meeting
A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population
Michelle Petri¹, Kenneth C. Kalunian², Murray Urowitz³, David A. Isenberg⁴, Richard Furie⁵, MaryAnn Morgan-Cox⁶, Maria Silk⁷, Ernst R. Dow⁸, Richard Higgs⁷, Steven Watts⁷ and Matthew D Linnik⁹, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁵North Shore University Hospital, Great Neck, NY, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Indianapolis, IN, ⁸Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁹Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Registration trials for SLE therapeutics require large numbers of patients with active disease, which in turn necessitates the trials be multinational with many participating…
Abstract Number: 499 • 2016 ACR/ARHP Annual Meeting
High Levels of Mir-451a Differentiate Patients at Risk of Developing RA from Healthy Controls
Klára Prajzlerová¹, Veronika Hrušková², Petra Hánová¹, Heřman F Mann¹, Karel Pavelka¹, Jiří Vencovský³, Ladislav Šenolt¹ and Mária Filková¹, ¹Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, Faculty of Science, Charles University in Prague, Prague, Czech Republic, ³Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
Background/Purpose: Individuals with clinically suspect arthralgia (CSA) with positivity of antibodies to citrullinated protein antigens (ACPA) have articular symptoms without clinical signs of arthritis. CSA…
Abstract Number: 704 • 2016 ACR/ARHP Annual Meeting
Does Change in Disease Activity over One Year Result in Change in Health-Related Quality of Life in Early Axial Spondyloarthritis Patients?
Miranda van Lunteren¹, Zineb Ez-Zaitouni¹, Pauline Bakker¹, Hanne Dagfinrud², Robert Landewé³, Maikel van Oosterhout⁴, Roberta Ramonda⁵, Floris van Gaalen¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Ziekenhuis, Gouda, Netherlands, ⁵Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In axial Spondyloarthritis (axSpA), treatment is targeted at reducing disease activity with the aim of improving the health-related quality of life (HRQoL). Therefore, it…
Abstract Number: 1055 • 2016 ACR/ARHP Annual Meeting
Physical Activity Behavior in Men with Inflammatory Arthritis: A Cross-Sectional Register Based Study of Physical Activity Correlates, Motivators, Barriers and Preferences
Nanna Maria Hammer¹, Julie Midtgaard², Merete Lund Hetland^3,4, Niels Steen Krogh⁵ and Bente Appel Esbensen^1,6, ¹Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet, Glostrup, Denmark, The DANBIO registry and Copenhagen Center for Arthritis Research, Glostrup, Denmark, ²Section of Social Medicine, University of Copenhagen, Copenhagen, Denmark, Department of Public Health, Copenhagen, Denmark, ³Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Denmark, Copenhagen, Denmark, ⁴Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ⁵Zitelab, Frederiksberg, Denmark, ⁶Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen Copenhagen, Denmark, Copenhagen, Denmark
Background/Purpose: While physical activity (PA) has been recommended as a part of the non-pharmacological management of inflammatory arthritis (IA), previous research within this area has…
Abstract Number: 1437 • 2016 ACR/ARHP Annual Meeting
Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis
Aranzazu Mediero¹, Tuere Wilder², Bhama Ramkhelawon³, Kathryn Moore³ and Bruce Cronstein⁴, ¹Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, ²Department of Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY, ³Leon H. Charney Division of Cardiology, Department of Medicine,, NYU School of Medicine, New York, NY, ⁴Medicine, Division of Rheumatology, NYU School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of joints. Netrin-1, a laminin-like matrix protein that acts as a…
Abstract Number: 1698 • 2016 ACR/ARHP Annual Meeting
Late Onset Psoriatic Arthritis in a Longitudinal Cohort: Disease Presentation, Activity over Time and Prognosis
Ari Polachek¹, Roa'a Al Johani², Suzanne Li¹, Vinod Chandran¹ and Dafna D Gladman³, ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Medicine, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) often develops between the 3rd to 5th decades of life. However, little is known about PsA activity and prognosis among patients…
Abstract Number: 2012 • 2016 ACR/ARHP Annual Meeting
Utility of the Lupus Low Disease Activity State Definition in Discriminating Responders in the Phase IIb Muse Trial of Anifrolumab in Systemic Lupus Erythematosus
E. Morand¹, A. Berglind², T. Sheytanova², R. Tummala³ and G. Illei³, ¹Monash University, Melbourne, Australia, ²AstraZeneca, Mölndal, Sweden, ³MedImmune, Gaithersburg, MD
Background/Purpose: Preliminary validation of a Lupus Low Disease Activity State (LLDAS) definition has demonstrated that LLDAS attainment is associated with reduced damage accrual in patients…
Abstract Number: 2501 • 2016 ACR/ARHP Annual Meeting
Radiographic Damage in Patients with RA Increases By 8.3% per Year Disease Duration, in the Era of Biologic Dmards. Results from the Scqm Cohort
Ruediger Mueller¹, Katja Heinimann², Rafael Sauter³, Hendrik Schulze-Koops⁴, Tuulikki Sokka-Isler⁵, Michael Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, MD, St. Gallen, Switzerland, ²Division of Rheumatology, Immunology and Rehabilitation, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Clinical Trials Unit, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Division for Rheumatology, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany, ⁵Rheumatology, Jyvaskyla Central Hospital, Jyvaskyla, Finland, ⁶Rheumatology, University of Colorado, Denver, CO, ⁷Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, inflammatory disease leading to joint destructions, if untreated. Treatment with biologic DMARDs has shown to favourably influence disease…
Abstract Number: 2768 • 2016 ACR/ARHP Annual Meeting
Prevalence of Obesity in Patients with Psoriatic Arthritis and Its Impact on the Severity of the Disease
Cecilia Zaffarana¹, Josefina Gallino Yanzi², Osvaldo Luis Cerda³, Margarita Landi⁴, Emilce Schneeberger¹ and Gustavo Citera¹, ¹Rheumatology Section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³IREP, CABA, Argentina, ⁴Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina
Background/Purpose: Epidemiological studies have found a high prevalence of obesity in patients with Psoriatic Arthritis (PsA). It was described the association between obesity and severity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].